Jay R. Campbell
Chief Business Officer (CBO)
Mr. Campbell joined Immutep in February 2017. He was previously Senior Director of Business Development and Investor Relations at Kolltan Pharmaceuticals, Inc., a privately-held biotechnology company developing biologic therapeutics targeting receptor tyrosine kinases for oncology and immunology, which was acquired by Celldex Therapeutics, Inc. in December 2016.
Prior to Kolltan, Mr. Campbell spent over 13 years working in the financial services industry and as an independent business development consultant, the majority of which was as an investment banker focusing on the life sciences industry. During this time, Mr Campbell was a business development consultant to ISTA Pharmaceuticals, Inc. in connection with the company’s review of strategic alternatives that culminated in the sale of the company to Bausch & Lomb in 2012.
Mr. Campbell previously worked at Maxim Group, Royal Bank of Scotland, ABN AMRO, Rothschild, and Schroders. Throughout his career, he has worked on over 25 successful financing, licensing, and M&A transactions representing more than $13.0 billion. Jay serves as a member of the board of directors of Update Pharma, Inc., a privately held clinical-stage small molecule company focused on developing overlooked or underutilized anti-cancer drugs. He received a BSBA in Management from Bucknell University and minored in Spanish.